Role of ATII cell senescence in influenza pathogenesis in aging
ATII细胞衰老在流感发病机制中的作用
基本信息
- 批准号:10741215
- 负责人:
- 金额:$ 44.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAcuteAcute Respiratory Distress SyndromeAgeAgingAlveolarAnimalsAntiviral AgentsAttenuatedBiological AssayBiologyBiophysicsC57BL/6 MouseCalorimetryCell AgingCell EnergeticsCell SeparationCell physiologyCellsCellular Metabolic ProcessCessation of lifeChronic Obstructive Pulmonary DiseaseCytidine Diphosphate CholineDevelopmentDiseaseDistalElderlyEnergy MetabolismEnsureEquipmentFunctional disorderGasesGenesGlycolysisGoalsHypoxemiaImmune responseInbred BALB C MiceInfectionInflammationInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A virusInfluenza vaccinationIon TransportLecithinLipidsLiquid substanceLower respiratory tract structureLungLung diseasesMaintenanceMetabolicMetabolic Clearance RateMetabolismMethodsMitochondriaModelingMusNon-Small-Cell Lung CarcinomaOutcomeOxidative PhosphorylationPET/CT scanPathogenesisPathway interactionsPhospholipidsPhysiologicalPhysiologyPopulationProcessProductionProteinsPublic HealthPulmonary InflammationRecyclingReproducibilityResearch PersonnelResourcesRespiratory DiseaseRoleSeveritiesSiteSurface TensionTestingViral PathogenesisVirus DiseasesVirus ReplicationWestern BlottingX-Ray Computed Tomographyage effectairway epitheliumalveolar type II cellexperimental studyextracellularflexibilityglucose uptakeimprovedin vivoinfluenza epidemicinfluenza infectioninfluenza virus vaccineinsightmouse modelnormal agingnovelolder patientpatient subsetspulmonary functionseasonal influenzasenescencesuccesssurfactantsurfactant productiontherapeutic targetvaccine accessvaccine efficacy
项目摘要
Alveolar type II (ATII) cells synthesize, secrete, and recycle surfactant proteins and lipids and regulate alveolar lining fluid
depth by alveolar fluid clearance. Because both processes require large amounts of energy, ATII cells contain large numbers
of mitochondria and mainly generate ATP by oxidative phosphorylation (OXPHOS). ATII cells are the primary site for
influenza A virus (IAV) replication in the distal lung and central players in the pathogenesis of IAV-induced ARDS.
Importantly, the elderly are over-represented in influenza-related fatalities. However, there is limited understanding of the
impact of either aging or IAV infection on ATII cell function, senescence, and energy metabolism. ATII cells isolated from
lungs of young (2-3 month-old) C57BL/6 mice primarily generate ATP by OXPHOS. In contrast, preliminary studies show
ATII cells from aging (27 month-old) mice undergo a glycolytic shift and downregulate OXPHOS, possibly as a result of
senescence. IAV infection of young mice causes a glycolytic shift and a decrease in OXPHOS which is reversed by CDP-
choline treatment, resulting in a net increase in total ATP production, attenuated hypoxemia, and reduced pulmonary
inflammation. IAV infection of aging mice causes more severe hypoxemia and further reduces OXPHOS without any
compensatory increase in glycolysis, resulting in a net decrease in total ATP production despite the increased energy
demands imposed by viral replication. Hence, it is hypothesized that influenza is more severe in the elderly because IAV
infection imposes additional energetic demands for viral replication on ATII cells that lack inherent metabolic flexibility
due to aging-associated senescence. By inhibiting de novo phospholipid synthesis, IAV also induces further mt dysfunction.
Together, these effects provoke an energy crisis and render ATII cells unable to perform their normal physiologic functions
(alveolar fluid clearance and surfactant synthesis), which results in progression to ARDS. It is further proposed that CDP-
choline treatment improves OXPHOS in ATII cells and increases their functional capacity, thereby improving influenza
outcomes. This hypothesis will be tested in two Specific Aims. Aim 1 will use a robust, reproducible, and relevant model
of IAV-induced ARDS in 21-24 month-old C57BL/6 and BALB/c mice to define effects of aging, IAV infection, and CDP-
choline treatment on ATII cell physiologic functions (surfactant production and alveolar fluid clearance), whole body
metabolism (by open circuit calorimetry), lung glucose uptake (by PET/CT), lung inflammation, and viral replication. Aim
2 will use a comprehensive battery of flow cytometric assays and Western blot to quantify the level of senescence in ATII
cells isolated from the lungs of mock- and IAV-infected young and aging mice and will analyze the impact of aging, IAV
infection, and CDP-choline treatment on ATII cell energetics by extracellular flux analysis. Proposed experiments will
provide novel mechanistic insights into the contribution of ATII cell dysfunction and senescence to development of more
severe influenza in the elderly and will generate fundamental new information relevant to many pulmonary diseases of
aging, such as COPD, IPF, and non-small cell lung cancer.
肺泡II型(ATII)细胞合成、分泌和回收表面活性蛋白和脂质,并调节肺泡衬里液
肺泡液体清除深度。由于这两个过程都需要大量的能量,ATII细胞含有大量的
主要通过氧化磷酸化(OXPHOS)产生ATP。ATII细胞是
甲型流感病毒(IAV)在远端肺中的复制和IAV诱导的ARDS发病机制中的中心参与者。
重要的是,老年人在流感相关死亡中所占比例过高。然而,人们对这一问题的认识有限。
衰老或IAV感染对ATII细胞功能、衰老和能量代谢影响。ATII细胞分离自
年幼(2-3月龄)C57 BL/6小鼠的肺主要通过OXPHOS产生ATP。相反,初步研究表明,
来自衰老(27个月大)小鼠的ATII细胞经历糖酵解转变并下调OXPHOS,这可能是
衰老IAV感染幼鼠引起糖酵解转变和OXPHOS减少,CDP-
胆碱治疗,导致总ATP产生的净增加,减弱低氧血症,并减少肺动脉高压。
炎症老龄小鼠的IAV感染引起更严重的低氧血症,并进一步降低OXPHOS,而没有任何
糖酵解的代偿性增加,导致总ATP产量的净减少,尽管能量增加
病毒复制的需求。因此,假设流感在老年人中更严重,因为IAV
感染对缺乏固有代谢灵活性的ATII细胞上的病毒复制施加了额外的能量需求
由于衰老相关的衰老。通过抑制从头磷脂合成,IAV还诱导进一步的mt功能障碍。
总之,这些影响引起能量危机,并使ATII细胞无法执行其正常的生理功能
(肺泡液清除和表面活性剂合成),导致进展为急性呼吸窘迫综合征。此外,还建议CDP-
胆碱处理改善ATII细胞中的OXPHOS,并增加其功能能力,从而改善流感
结果。这一假设将在两个具体目标中得到检验。目标1将使用一个稳健的、可重复的和相关的模型
在21-24月龄的C57 BL/6和BALB/c小鼠中IAV诱导的ARDS的影响,以确定衰老、IAV感染和CDP-
胆碱治疗对ATII细胞生理功能(表面活性剂产生和肺泡液清除)的影响,全身
代谢(通过开路量热法)、肺葡萄糖摄取(通过PET/CT)、肺部炎症和病毒复制。目的
2将使用一套全面的流式细胞术检测和蛋白质印迹来量化ATII衰老的水平,
从模拟和IAV感染的年轻和衰老小鼠的肺中分离的细胞,并将分析衰老、IAV
感染和CDP-胆碱处理对ATII细胞能量学的影响。拟议的实验将
为ATII细胞功能障碍和衰老对更多细胞发育的贡献提供了新的机制见解。
老年人中的严重流感,并将产生与许多肺部疾病相关的基本新信息,
衰老,如COPD、IPF和非小细胞肺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAN CHRISTOPHER DAVIS其他文献
IAN CHRISTOPHER DAVIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAN CHRISTOPHER DAVIS', 18)}}的其他基金
Role of alterations in the ATII cell lipidome in influenza pathogenesis
ATII 细胞脂质组变化在流感发病机制中的作用
- 批准号:
9917813 - 财政年份:2017
- 资助金额:
$ 44.83万 - 项目类别:
Role of alterations in the ATII cell lipidome in influenza pathogenesis
ATII 细胞脂质组变化在流感发病机制中的作用
- 批准号:
9298233 - 财政年份:2017
- 资助金额:
$ 44.83万 - 项目类别:
The role of adenosine in the pathogenesis of influenza
腺苷在流感发病机制中的作用
- 批准号:
8080241 - 财政年份:2010
- 资助金额:
$ 44.83万 - 项目类别:
The role of adenosine in the pathogenesis of influenza
腺苷在流感发病机制中的作用
- 批准号:
8078108 - 财政年份:2010
- 资助金额:
$ 44.83万 - 项目类别:
The role of adenosine in the pathogenesis of influenza
腺苷在流感发病机制中的作用
- 批准号:
8298185 - 财政年份:2010
- 资助金额:
$ 44.83万 - 项目类别:
The role of adenosine in the pathogenesis of influenza
腺苷在流感发病机制中的作用
- 批准号:
8689136 - 财政年份:2010
- 资助金额:
$ 44.83万 - 项目类别:
The role of adenosine in the pathogenesis of influenza
腺苷在流感发病机制中的作用
- 批准号:
8509777 - 财政年份:2010
- 资助金额:
$ 44.83万 - 项目类别:
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS
呼吸道合胞病毒对 Na 转运的抑制
- 批准号:
6931548 - 财政年份:2003
- 资助金额:
$ 44.83万 - 项目类别:
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS
呼吸道合胞病毒对 Na 转运的抑制
- 批准号:
7110384 - 财政年份:2003
- 资助金额:
$ 44.83万 - 项目类别:
Na+ TRANSPORT INHIBITION BY RESPIRATORY SYNCYTIAL VIRUS
呼吸道合胞病毒对 Na 转运的抑制
- 批准号:
6802676 - 财政年份:2003
- 资助金额:
$ 44.83万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 44.83万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 44.83万 - 项目类别: